Implications of the Provenge Survival Data for Clinical Practice
Implications of the Provenge Survival Data for Clinical Practice
Manish Kohli, MD, Mayo Clinic
20090406
2009 May 6
Implications of the Provenge Survival Data for Clinical Practice
2009 May 6, Manish Kohli, MD, Mayo Clinic
Data showing a survival advantage with Provenge support immunotherapy as a viable therapeutic option for prostate cancer progressing after ADT.
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
